Zoledronic acid oral - Thar Pharmaceuticals

Drug Profile

Zoledronic acid oral - Thar Pharmaceuticals

Alternative Names: T 121E01F; T121

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Thar Pharmaceuticals
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Complex regional pain syndromes
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Complex regional pain syndromes

Most Recent Events

  • 26 Feb 2013 Oral zoledronic acid is available for licensing. www.tharpharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top